Evidence map›Paper›PMID 41765025›Full record

SynthesisLancet (London, England)2026

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.

Amar U Kishan, Yilun Sun, Christopher C Parker, Paul Sargos, Matthew R Sydes, Sylvie Chabaud, Meryem Brihoum, Tahmineh Romero Kalbasi, Michael L Steinberg, Luca F Valle and 23 more

Erratum issuedAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Lancet (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.
Yilun SunDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Christopher C ParkerThe Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
Paul SargosInstitut Bergonié, Bordeaux, France.
Matthew R SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Sylvie ChabaudClinical Research Department, Centre Léon Bérard, Lyon, France.
Meryem BrihoumUnicancer, Paris, France.
Tahmineh Romero KalbasiDepartment of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA, USA.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Luca F ValleDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Kekoa TaparraDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA; School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
Jonathan E ShoagDepartment of Urology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Jorge A GarciaDepartment of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Jason R BrownDepartment of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Matthew B RettigDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Adam E SingerDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Robert E ReiterDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Scott EggenerDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Wayne BrisbaneDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Soumyajit RoyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Nicholas G ZaorskyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Angela Y JiaDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Ting Martin MaDepartment of Radiation Oncology, University of Washington, Seattle, WA, USA.
Nicholas G NickolsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, Greater Los Angeles VA, Los Angeles, CA, USA.
Jason A EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Osama MohamadDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; Department of American University of Beirut, Beirut, Lebanon.
James J DignamDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA; NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
Wendy F SeiferheldNRG Oncology Statistics and Data Management Center, Philadelphia, PA.
Alan PollackDepartment of Radiation Oncology, Miller School of Medicine and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Howard M SandlerDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Paul L NguyenDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA.
Pascal PommierClinical Research Department, Centre Léon Bérard, Lyon, France; Department of Radiotherapy, Institut Curie, Paris, France.
Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Funding

Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam · 2014 to 2026
$146.4M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
Reducing toxicity from prostate cancer radiotherapy through genetics and technologyR37CA292795 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Amar U Kishan · 2024 to 2026
$1.1M
NCI NIH HHS R37 CA292795NCI NIH HHS T32 CA009213NCI NIH HHS U10 CA180822
6 · The paper itself

Abstract

backgroundAdding hormone therapy to definitive radiotherapy in localised prostate cancer improves overall survival, but whether it similarly improves overall survival in the context of postoperative radiotherapy (PORT) after radical prostatectomy is unclear. Herein, we report an individual patient data (IPD) meta-analysis of randomised trials aimed at quantifying the benefit of adding hormonal therapy to PORT.

methodsThis was an IPD meta-analysis that identified randomised, phase 3 trials of PORT with or without hormone therapy. A systematic literature search of MEDLINE, Embase, trial registries, the Web of Science, Scopus, and relevant conference proceedings was done on Dec 15, 2024. IPD were available via the MARCAP consortium. The primary outcome was overall survival. Meta-analyses evaluated the benefit of adding hormone therapy, short-term hormone therapy (4-6 months), or long-term hormone therapy (24 months) to PORT. Tests for interaction based on pre-PORT prostate-specific antigen (PSA) and duration of hormone therapy were evaluated and non-linear associations between pre-PORT PSA and overall survival were modelled. This study was done under the master protocol of the MARCAP Consortium (PROSPERO registration CRD42019134376).

findingsIPD were available for six randomised trials including 6057 patients with a median follow-up of 9·0 years (IQR 7·2-10·7 years). Adding hormone therapy to radiotherapy did not significantly improve overall survival (hazard ratio [HR] 0·87, 95% CI 0·76-1·01, p=0·06). There was no significant interaction between hormone therapy duration and this effect (p

interpretationOur findings, we believe, provide the strongest level of evidence to date suggesting there might be no meaningful overall survival benefit to adding hormone therapy, either short-term or long-term hormone therapy, to PORT for PSA 0·5 ng/mL or less, with no apparent difference in efficacy for short-term versus long-term hormone therapy. There is an unmet need to identify biomarkers to predict potential hormone therapy benefit.

fundingNational Institutes of Health.

Indexed as

Androgen AntagonistsAntineoplastic Agents, HormonalNeoplasm Recurrence, LocalProstatic NeoplasmsAgedCombined Modality TherapyHumansMaleProstatectomyProstate-Specific AntigenRadiotherapy, AdjuvantRandomized Controlled Trials as TopicAndrogen AntagonistsAntineoplastic Agents, HormonalProstate-Specific Antigen

Identifiers

PMID41765025
PMCPMC13637963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.